Why the study?
Should anticoagulant dosing in children be based on pediatric pharmacokinetic and pharmacodynamic data rather than extrapolated from adults?
Should anticoagulant dosing in children be based on pediatric pharmacokinetic and pharmacodynamic data rather than extrapolated from adults?
Anticoagulant dosing in children should be derived from pediatric-specific pharmacokinetic and pharmacodynamic data due to differences in metabolism and hemostatic systems compared to adults.
Answers are grounded in this paper and cite their sources.
May inform pediatric anticoagulant dosing via PK/PD data; leaves open prospective outcome trials.
With the increasing incidence of venous thromboembolic events in children, there has also been a concurrent increase in the use of anticoagulants in children. It is imperative that dosing recommendations of anticoagulants be derived from pharmacokinetic- and pharmacodynamic-based data in children and not simply extrapolated from data based on adults. Medications for children are often based on weight or body surface area, and are often distributed and metabolized differently as well. Furthermore, the hemostatic system in neonates and infants differs from that of older children and adults, and targets for therapy may differ. For these reasons, dosing guidelines for all antithrombotic medications should be based on pharmacokinetic and pharmacodynamic data. The authors reviewed pharmacokinetic and pharmacodynamic studies of anticoagulants in children and make dosing recommendations based on study findings.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: